Immunogenicity and Safety of Inactivated Sabin-Strain Polio Vaccine “PoliovacSin”: Clinical Trials Phase I and II
Authors:
- Anastasia PiniaevaAPAnastasia Piniaeva
- Georgy IgnatyevGIGeorgy Ignatyev
- Liubov KozlovskayaLKLiubov Kozlovskaya
- Yury IvinYIYury Ivin
- Anastasia KovpakAKAnastasia Kovpak
- Alexander IvanovAIAlexander Ivanov
- Anna ShishovaASAnna Shishova
- Liliia AntonovaLALiliia Antonova
- Yusuf KhapchaevYKYusuf Khapchaev
- Irina FeldbliumIFIrina Feldblium
- Olga IvanovaOIOlga Ivanova
- Aleksandra SiniuginaASAleksandra Siniugina
Open Access
Abstract
Global polio eradication requires both safe and effective vaccines, and safe production processes. Sabin oral poliomyelitis vaccine (OPV) strains can evolve to virulent viruses and result in poliomyelitis outbreaks, and conventional inactivated poliomyelitis vaccine (Salk-IPV) production includes accumulation of large stocks of neurovirulent wild polioviruses. Therefore, IPV based on attenuated OPV strains seems a viable option. To increase the global supply of affordable inactivated vaccine in the still not-polio free world we developed an IPV made from the Sabin strains–PoliovacSin. Clinical trials included participants 18–60 years of age. A phase I single-center, randomized, double-blind placebo-controlled clinical trial included 60 participants, who received one dose of PoliovacSin or Placebo. A phase II multicenter, randomized, double-blind, comparative clinical trial included 200 participants, who received one dose of PoliovacSin or Imovax Polio. All vaccinations were well tolerated, and PoliovacSin had a comparable safety profile to the Placebo or the reference Imovax Polio preparations. A significant increase in neutralizing antibody levels to polioviruses types 1–3 (Sabin and wild) was observed in PoliovacSin and Imovax Polio vaccinated groups. Therefore, clinical trials confirmed good tolerability, low reactogenicity, and high safety profile of the PoliovacSin and its pronounced immunogenic properties. The preparation was approved for clinical trials involving infants.Keywords
This publication has 26 references indexed in Scilit:
- Development and introduction of inactivated poliovirus vaccines derived from Sabin strains in JapanVaccine, 2016
- Vaccine-associated paralytic poliomyelitis in Russian Federation during the period of changes in vaccination schedule (2006-2013 y.y.)Problems of Virology, 2016
- Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trialThe Lancet Infectious Diseases, 2015
- Production of high titer attenuated poliovirus strains on the serum-free PER.C6® cell culture platform for the generation of safe and affordable next generation IPVVaccine, 2015
- Polio-Free Certification and Lessons Learned — South-East Asia Region, March 20142014
- Vaccine-Derived PoliovirusesThe Journal of Infectious Diseases, 2014
- Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strainsExpert Review of Vaccines, 2011
- Multivariate data analysis on historical IPV production data for better process understanding and future improvementsBiotechnology and Bioengineering, 2010
- Polio eradication: the OPV paradoxReviews in Medical Virology, 2003
- Strategies for the Global Eradication of Poliomyelitis by the Year 2000New England Journal of Medicine, 1991